This move is archived. Current quotes and coverage live on the stock page.
Follow GUD
Knight Therapeutics Inc. shares surged by 3.70% in the latest trading session, reflecting positive investor sentiment.
Knight Therapeutics Inc. (GUD.TO) saw its stock price close at CA$9.80 after a 3.70% gain. This rise comes amid strong performance metrics and strategic corporate actions that have caught investors' attention.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$1.14B
P/E
72.5x
52W high
$11.89
52W low
$5.66
1W change
+2.47%
Beta
0.02
Analyst Price Targets
Based on analyst covering GUD · as of Nov 10, 2026
Wall Street analysts forecast GUD stock price to rise 8.4% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$12.57
+8.4% Upside
Previously C$11.65 on Oct 19, 2026
Current Price
C$11.60
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.1%
Annualized
90-Day Vol
26.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.87
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.31 | C$11.37 – C$13.33 |
| 60 trading days | C$13.07 | C$11.67 – C$14.62 |
| 90 trading days | C$13.87 | C$12.08 – C$15.92 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent stock price increase shows growing confidence in Knight Therapeutics' operational strategies and market positioning, making it a stock to watch in the healthcare sector.
Knight Therapeutics Inc. sees a 3.70% increase in stock price.
With a market cap of CA$927.8 million, Knight's recent performance highlights its potential for growth in the competitive pharmaceutical landscape.
Bull case
Investors are optimistic about Knight's strategic initiatives, like repaying its revolving credit facility and impressive revenue growth reported in recent earnings. These factors create a solid foundation for future growth.
Bear case
Despite the positive movement, Knight Therapeutics' high P/E ratio of 157.5 may turn off some investors, as it suggests the stock could be overvalued compared to its earnings.
Recent Performance Highlights
Knight Therapeutics' stock has shown resilience, closing at CA$9.80 after a 3.70% increase. This performance is especially noteworthy given the company's recent financial results, which reported a significant year-over-year revenue increase.
Strategic Moves Fueling Investor Confidence
The company's repayment of its revolving credit facility and focus on growth strategies have positively influenced investor sentiment. Knight's recent earnings report revealed a remarkable 68-69% increase in revenues, further solidifying its market position.
Valuation Considerations
While the stock's recent gains are encouraging, potential investors should consider the high P/E ratio of 157.5, which may indicate overvaluation. It's essential to weigh the company's growth prospects against its current valuation metrics before making investment decisions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
